Cargando…
Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
β-Thalassaemia is one of the most common monogenic diseases with no effective cure in the majority of patients. Unbalanced production of α-globin in the presence of defective synthesis of β-globin is the primary mechanism for anaemia in β-thalassaemia. Clinical genetic data accumulated over three de...
Autores principales: | Mettananda, Sachith, Yasara, Nirmani, Fisher, Christopher A., Taylor, Stephen, Gibbons, Richard, Higgs, Doug |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690964/ https://www.ncbi.nlm.nih.gov/pubmed/31406232 http://dx.doi.org/10.1038/s41598-019-48204-2 |
Ejemplares similares
-
Genetic and Epigenetic Therapies for β-Thalassaemia by Altering the Expression of α-Globin Gene
por: Mettananda, Sachith
Publicado: (2021) -
Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial
por: Yasara, Nirmani, et al.
Publicado: (2020) -
A randomised double-blind placebo-controlled clinical trial of oral hydroxyurea for transfusion-dependent β-thalassaemia
por: Yasara, Nirmani, et al.
Publicado: (2022) -
A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemic
por: Yasara, Nirmani, et al.
Publicado: (2021) -
Reciprocal regulation of γ-globin expression by exo-miRNAs: Relevance to γ-globin silencing in β-thalassemia major
por: Sun, Kuo-Ting, et al.
Publicado: (2017)